Merck Licenses Hansoh's GLP-1 Agonist for Obesity
Merck Inc., (known as MSD outside of the United States and Canada), and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement for HS 10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS 10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales. Hansoh Pharma may co-promote or solely commercialize HS 10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins